

Table S1. Non-synonymous mutations for characterizing the variants.

	ORF1a	ORF1b	S		ORF3a	M	ORF7a	ORF8	N
Alpha	T1001I A1708D I2230T	P314L	N501Y A570D D614G P681H	T716I S982A D1118H				Q27* R52I Y73C	(D3L) R203K G204R S235F
Beta	T265I K3353R	P314L	E484K N501Y D614G		Q57H				T205I
Gamma	S1188L K1795Q	P314L E1264D	L18F T20N P26S D138Y E484K	N501Y D614G H655Y T1027I V1176F	S253P			E92K	P80R R203K G204R
Delta	P2287S T3255I T3646A	P314L G662S P1000L	T19R L452R T478K	D614G P681R D950N	S26L	I82T	T120I		D63G R203M D377Y
Epsilon	T265I	P314L	L452R D614G		Q57H				T205I
Zeta	L3468V L3930F	P314L	E484K D614G V1176F						A119S R203K G204R M234I
Eta	T2007I	(P314F)	A67V E484K D614G	Q677H F888L		I82T			T205I
Theta	L3201P D3681E L3930F	P314L A1291V	E484K N501Y D614G P681H	E1092K H1101Y V1176F					R203K G204R
Iota	T265I L3201P	P314L	D614G		P42L Q57H			T11I	M234I
Kappa	T1567I T3646A	P314L M1352I	L452R D614G P681R		S26L				R203M D377Y
Lambda	T1246I P2287S F2387V L3201P T3255I	P314L	T76I L452Q F490S D614G T859N						P13L R203K G204R G214C
D614G		P314L	D614G						
D614G+		P314L	D614G						R203K G204R
Japan		P314L P1567L R2684I	D614G						R203K G204R M234I

Table S2. Characteristics and treatment of deceased patients

Patient No.	Sex	Age	Duration of hospitalization	Obesity	Current or ex-Smoker	Comorbidity	Treatment
Group A							
1	Male	70s	3	No	Yes	COPD, Cancer	DEX, RDV
2	Female	70s	19	No	No	HTN	DEX, mPSL
3	Female	80s	28	No	No	HTN, CVD	DEX, mPSL, RDV
4	Male	80s	6	No	No	HTN, COPD, Cancer	DEX
Group B							
1	Male	70s	21	No	No	HTN, COPD, CKD	mPSL, RDV
2	Female	70s	10	Yes	Yes	HTN, DLP, COPD, CKD	mPSL
3	Male	70s	26	Yes	No	HTN, DLP, DM	DEX, mPSL
4	Male	70s	21	No	Yes	HTN, DM, CVD	DEX, mPSL
5	Male	80s	5	No	Yes	DM, COPD	mPSL
6	Male	80s	16	No	Yes	HTN, DM, CVD, CKD, Cancer	DEX, mPSL

COPD: chronic obstructive pulmonary disease, HTN: hypertension, CVD: cardiovascular disease, DLP: dyslipidemia, DM: diabetes mellitus, DEX: dexamethasone, RDV: remdesivir, mPSL: methylprednisolone